UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 0426, 2026

Arcadia Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-37383	81-0571538
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5956 Sherry Lane Suite 2000
Dallas, Texas		75225
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 214 974-8921

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	RKDA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 DepartureResults of DirectorsOperations orand CertainFinancial Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersCondition.

On March 26, 2026 Arcadia Biosciences, Inc. (bthe “Company”) ~~Resignation~~ issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025. A copy of ~~Directors~~the press release is furnished as Exhibit 99.1, and the Company's annual financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference.

OnThe ~~February~~information 4,furnished ~~2026~~in this Form 8-K, ~~each~~the ofpress ~~Albert~~release D.attached ~~Bolles,~~as PhExhibit 99.D.1, aand ~~director~~the ~~and~~financial ~~member~~information ofattached ~~the~~as ~~Compensation~~Exhibit ~~Committee~~99.2, ofshall ~~the~~not ~~board~~be ofdeemed ~~directors~~“filed” ~~(the~~for ~~"Board")~~purposes of ~~Arcadia~~Section ~~Biosciences,~~18 ~~Inc.~~of (the ~~"Company"),~~Securities ~~and~~Exchange ~~Deborah~~Act ~~Carosella~~of 1934, aas ~~director~~amended, ~~and~~or ~~member~~otherwise ofsubject to the ~~Compensation~~liabilities ~~Committee~~of ~~and~~that ~~Nominating~~section ~~and~~or ~~Governance~~Sections ~~Committee~~11 and 12(a)(2) of the ~~Board~~Securities Act of 1933, ~~notified~~as ~~the~~amended. ~~Company~~The ~~that~~information ~~effective~~contained asin ofthis ~~February~~Item 42.02, ~~2026,~~in ~~such~~the ~~person~~press ~~was~~release ~~resigning~~attached as aExhibit ~~director~~99.1, ~~of the Company~~ and ~~all~~in ~~subsidiaries of~~ the ~~Company~~financial ofinformation ~~which~~attached ~~such~~as ~~person~~Exhibit ~~was~~99.2, ashall ~~director. Their~~not ~~resignation~~be ~~was~~incorporated ~~not~~by ~~because~~reference ofinto any ~~disagreement~~filing with the ~~Company~~U.S. orSecurities ~~the~~and ~~Board~~Exchange onCommission ~~any~~made ~~matter~~by ~~relating to~~ the Company~~’s operations~~, ~~policies,~~whether ~~practices~~made before or ~~financial~~after ~~statements. Each~~the ~~person~~date ~~agreed~~hereof, toregardless beof ~~available~~any togeneral ~~provide~~incorporation ~~assistance~~language asin ansuch ~~advisor~~filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

None.


Exhibit No.		Description

99.1		Arcadia Biosciences Announces Fourth-Quarter and Full Year 2025 Financial Results and Business Highlights
99.2		Arcadia Biosciences Full Year 2025 Financial Information
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~thereunto duly authorized.

			ARCADIA BIOSCIENCES, INC.
Date:	~~February~~March 626, 2026	By:	/s/ THOMAS J. SCHAEFER
			Thomas J. Schaefer, Chief Executive Officer

Filing Compare · Arcadia Biosciences, Inc.